Home » Topics » Regulatory » EMA

EMA
RSS

Regeneron's Eylea receives second U.S. approval

Sep. 27, 2012

Votubia recommended for approval in Europe

Sep. 26, 2012

EMA committee recommends approval of enzyme-based debriding agent for burn care

Sep. 26, 2012

Avastin recommended for approval of recurrent, platinum-sensitive ovarian cancer in Europe

Sep. 26, 2012

Novartis obtains positive CHMP opinions for Galvus and Eucreas

Sep. 26, 2012

CHMP gives positive opinion on Cialis in new indication

Sep. 26, 2012

CHMP recommends VEGF Trap-Eye in wet AMD

Sep. 26, 2012

CHMP recommends expanded approval of Trajenta tablets

Sep. 25, 2012

CHMP recommends Constella in IBS-C

Sep. 25, 2012

EMA committee recommends approval of new apixaban indication

Sep. 25, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...